VREX
Another analyst wants in
Varex Imaging just picked up a new cheerleader: Zacks Research upgraded the medical-imaging parts maker to Strong-Buy from Hold. That matters because analyst calls can act like a tiny megaphone — not a full thesis reset, but enough to nudge sentiment when a stock is already trying to find its groove.
The catch? The street still looks split
This isn’t a clean “everyone piled into the same trade” moment. The broader analyst crowd is still mixed, with a consensus rating sitting around Moderate Buy and a consensus price target of $16.17. So yes, the tone is getting more constructive — but the stock still has to prove it can earn the higher-fives.
Why investors should care
There’s more than just ratings drama here. Varex recently beat Q4 expectations with $0.19 EPS versus $0.14 expected and $209.6 million in revenue, then guided Q2 2026 EPS to $0.150–$0.250. That’s the kind of combo that can make a beaten-up industrial name feel a little less like a sad basement band and a little more like a comeback tour.
The fine print
The article also flagged a director sale of 4,510 shares, plus heavier institutional buying from names like JPMorgan, Assenagon, and Rice Hall James. Big picture: the upgrade is helpful, but the real stock move still depends on whether Varex can keep turning decent operating results into something that looks like a durable recovery.